Metraipolis › archive › dc_463278795e83

Cost-Effectiveness Analysis of Nirsevimab for Respiratory Syncytial Virus Disease Prevention in Newborns of Hong Kong — Europe PMC PMID:41031614

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41031614
DOI
10.1111/irv.70153
License (as archived)
solo-consultazione
Archived
2026-11-09T16:19:50.632Z
SHA-256 of the archived text
30145af6790e8f58dc46599e84ffc2bf5807d113fdefa4b08bcd0738beabca0b
Stable URL of this page
https://metraipolis.com/documento/dc_463278795e83

How to cite

Cost-Effectiveness Analysis of Nirsevimab for Respiratory Syncytial Virus Disease Prevention in Newborns of Hong Kong — Europe PMC PMID:41031614 — Europe PMC (en), https://europepmc.org/article/MED/41031614 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_463278795e83 (Metraipolis archive dc_463278795e83, sha256 30145af6790e8f58dc46599e84ffc2bf5807d113fdefa4b08bcd0738beabca0b)
BibTeX
@misc{dc463278795e83,
  title = {Cost-Effectiveness Analysis of Nirsevimab for Respiratory Syncytial Virus Disease Prevention in Newborns of Hong Kong — Europe PMC PMID:41031614},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41031614},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_463278795e83; sha256 30145af6790e8f58dc46599e84ffc2bf5807d113fdefa4b08bcd0738beabca0b},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41031614. Agents can read the archived copy with the MCP tool read_document.